Intellipharmaceutics International Inc. (IPCI)의 가격은 얼마입니까?

Intellipharmaceutics International Inc. (IPCI)의 가격은 $0.05897422입니다.

Intellipharmaceutics International Inc. (IPCI)의 시가 총액은 무엇입니까?

Intellipharmaceutics International Inc. (IPCI)의 시가 총액은 $1.64M입니다.

Intellipharmaceutics International Inc. (IPCI) 수익

Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.

연도	수익	변화
2026 (TTM)	$-3.17M	9.75%
2022	$-2.89M	0.00%
2021	$-2.89M	-45.11%
2020	$-5.26M	56.62%
2019	$-3.36M	-75.57%
2018	$-13.75M	55.21%
2017	$-8.86M	-12.68%
2016	$-10.14M	36.40%
2015	$-7.44M	92.83%
2014	$-3.86M	-66.45%
2013	$-11.50M	135.54%
2012	$-4.88M	95.22%
2011	$-2.50M	-56.34%
2010	$-5.73M	-55.76%
2008	$-12.94M	-56.95%
2007	$-30.07M	-49.08%
2006	$-59.05M	-25.61%
2005	$-79.37M	13.77%
2004	$-69.77M	173.92%
2003	$-25.47M	104.32%
2002	$-12.47M	36.27%
2001	$-9.15M	41.00%
2000	$-6.49M	0.00%
1999	0.00	0.00%

연도

수익

변화

2026 (TTM)

$-3.17M

9.75%

2022

$-2.89M

0.00%

2021

$-2.89M

-45.11%

2020

$-5.26M

56.62%

2019

$-3.36M

-75.57%

2018

$-13.75M

55.21%

2017

$-8.86M

-12.68%

2016

$-10.14M

36.40%

2015

$-7.44M

92.83%

2014

$-3.86M

-66.45%

2013

$-11.50M

135.54%

2012

$-4.88M

95.22%

2011

$-2.50M

-56.34%

2010

$-5.73M

-55.76%

2008

$-12.94M

-56.95%

2007

$-30.07M

-49.08%

2006

$-59.05M

-25.61%

2005

$-79.37M

13.77%

2004

$-69.77M

173.92%

2003

$-25.47M

104.32%

2002

$-12.47M

36.27%

2001

$-9.15M

41.00%

2000

$-6.49M

0.00%

1999

0.00

0.00%

회사	수익	수익 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-166,580.77%	US
Moderna, Inc. MRNA.US	$-3.09B	97,328.60%	US
CSL Limited CSL.AX	$-4.02B	126,654.91%	AU
Argenx SE ARGX.US	$1.95B	-61,664.34%	NL
Lonza Group AG LONN.SW	-	-	CH

회사

수익

수익 차이

국가